Kura Oncology Inc. (NASDAQ:KURA) shares climbed 11.0% in pre-market trading on Tuesday after President and Chief Executive Officer Troy Edward Wilson purchased approximately $1.24 million worth of the company’s shares.
According to a filing with the U.S. Securities and Exchange Commission, Wilson acquired 100,000 Kura Oncology shares on August 24, 2026, providing a notable signal of insider confidence in the biotechnology company.
CEO Purchases 100,000 Kura Oncology Shares
Wilson bought the shares at a weighted average price of $12.39 each, with the transaction completed through multiple trades at prices ranging from $11.47 to $12.85 per share.
The acquisition increased Wilson’s indirect ownership through the One Fish Two Fish Revocable Trust to 479,194 shares.
In addition to those holdings, the Kura Oncology CEO directly owns 435,456 shares and has an indirect interest in another 300,000 shares through the Lorax Charitable Remainder Unitrust.
Insider Purchase Draws Investor Attention
The scale of Wilson’s purchase attracted attention from investors ahead of Tuesday’s opening bell, helping send Kura Oncology shares sharply higher in pre-market trading.
Insider buying can be closely watched by market participants because executives committing their own capital to a company may be interpreted as a sign of confidence in its longer-term prospects. Such transactions, however, do not guarantee future share-price performance.
In Kura Oncology’s case, the $1.24 million investment is particularly notable given that it was made by the company’s president and chief executive and materially increased his exposure to the stock.
The market’s immediate reaction was positive, with Kura Oncology shares gaining 11.0% before the opening bell as investors assessed the significance of the CEO’s increased stake.
Kura Oncology stock price
